Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

Clinical pharmacology and therapeutics - 1 Nov 2009

You J H S, Tsui K K N, Wong R S M, Cheng G

Abstract excerpt

The US Food and Drug Administration has updated the label information for warfarin to encourage the use of genetic information before initiating treatment with the drug. We used decision-tree modeling to simulate the outcomes of CYP2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotype-guided dosing in patients in whom warfarin therapy is to be initiated. The inputs for the model were derived from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Warfarin
Share to Cost-Benefit Analysis
Share to Decision Trees

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to International Normalized Ratio

Share to Monte Carlo Method

Share to Quality-Adjusted Life Years

Share to United States Food and Drug Administration

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 19571807
DOI: 10.1038/clpt.2009.104

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.PMID 19571807Read ↗

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.Semantic proximity Read ↗

Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.Semantic proximity Read ↗

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Semantic proximity Read ↗

Pharmacoeconomic evaluation of warfarin pharmacogenomics.Semantic proximity Read ↗

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.Semantic proximity Read ↗

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.Semantic proximity Read ↗

Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of warfarin.Semantic proximity Read ↗

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.Semantic proximity Read ↗

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation.Semantic proximity Read ↗

A pharmacogenetic versus a clinical algorithm for warfarin dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.